These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38848734)

  • 1. Tumor-Associated Myeloid Cells Selective Delivery of a Therapeutic Tumor Nano-Vaccine for Overcoming Immune Barriers for Effective and Long-Term Cancer Immunotherapy.
    Wang C; Zhao J; Duan Y; Lin L; Zhang Q; Zheng H; Shan W; Wang X; Ren L
    Adv Healthc Mater; 2024 Oct; 13(26):e2401416. PubMed ID: 38848734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-pronged anti-cancer nanovaccines enpowered by exogenous/endogenous tumor-associated antigens.
    Yin M; Liu Z; Zhou Y; Li W; Yan J; Cao D; Yin L
    J Control Release; 2024 Sep; 373():358-369. PubMed ID: 39009083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Multifunctional Nanovaccines for Potent Personalized Immunotherapy of Acute Myeloid Leukemia.
    Zhang P; Wang T; Cui G; Ye R; Wan W; Liu T; Zheng Y; Zhong Z
    Adv Mater; 2024 Oct; 36(40):e2407189. PubMed ID: 39171954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucosylated Nanovaccines for Dendritic Cell-Targeted Antigen Delivery and Amplified Cancer Immunotherapy.
    Liu J; Cui Y; Cabral H; Tong A; Yue Q; Zhao L; Sun X; Mi P
    ACS Nano; 2024 Sep; 18(37):25826-25840. PubMed ID: 39196858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
    Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
    ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

  • 7. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
    Zhang Y; Song S; Liu C; Wang Y; Xian X; He Y; Wang J; Liu F; Sun S
    Cell Immunol; 2007 May; 247(1):18-27. PubMed ID: 17707782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A carrier-free nanovaccine combined with cancer immunotherapy overcomes gemcitabine resistance.
    Pan W; Wang Y; Chen G; Ma X; Min Y
    Biomaterials; 2025 Feb; 313():122788. PubMed ID: 39236628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells.
    Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M
    Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-Like Particles Presenting the FGF-2 Protein or Identified Antigenic Peptides Promoted Antitumor Immune Responses in Mice.
    Shu C; Sun P; Xie H; Huang W; Qi J; Ma Y
    Int J Nanomedicine; 2020; 15():1983-1996. PubMed ID: 32308382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Trop2 virus-like particles: a potential immunotherapeutic approach against pancreatic cancer.
    Cubas R; Zhang S; Li M; Chen C; Yao Q
    J Immunother; 2011 Apr; 34(3):251-63. PubMed ID: 21389873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model.
    Chu X; Li Y; Long Q; Xia Y; Yao Y; Sun W; Huang W; Yang X; Liu C; Ma Y
    Int J Nanomedicine; 2016; 11():2417-29. PubMed ID: 27313455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
    Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
    Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity.
    Patel JM; Vartabedian VF; Kim MC; He S; Kang SM; Selvaraj P
    Biotechnol Bioeng; 2015 Jun; 112(6):1102-10. PubMed ID: 25689082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel rapid modularized hepatitis B core virus-like particle-based platform for personalized cancer vaccine preparation via fixed-point coupling.
    Ji M; Zhu J; Xie XX; Liu DQ; Wang B; Yu Z; Liu RT
    Nanomedicine; 2020 Aug; 28():102223. PubMed ID: 32422220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy.
    Dang BN; Duwa R; Lee S; Kwon TK; Chang JH; Jeong JH; Yook S
    J Control Release; 2024 Aug; 372():587-608. PubMed ID: 38942083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel DEC-205 binding peptide to develop dendritic cell-targeting nanovaccine for cancer immunotherapy.
    Zheng J; Wang M; Pang L; Wang S; Kong Y; Zhu X; Zhou X; Wang X; Chen C; Ning H; Zhao W; Zhai W; Qi Y; Wu Y; Gao Y
    J Control Release; 2024 Sep; 373():568-582. PubMed ID: 39067792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
    Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
    Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.